Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 6, 2022; 10(4): 1263-1277
Published online Feb 6, 2022. doi: 10.12998/wjcc.v10.i4.1263
Sintilimab-induced autoimmune diabetes: A case report and review of the literature
Jing Yang, Ying Wang, Xiang-Min Tong
Jing Yang, Clinical Laboratory Center, Zhejiang Provincial People’s Hospital, Hangzhou 310014, Zhejiang Province, China
Ying Wang, Clinical Research Institute, Zhejiang Provincial People’s Hospital, Hangzhou 310014, Zhejiang Province, China
Xiang-Min Tong, Department of Hematology, Clinical Trial Institute, Zhejiang Provincial People’s Hospital, Hangzhou 310014, Zhejiang Province, China
Author contributions: Yang J contributed to data curation; Tong XM and Wang Y contributed to project administration and resources; Yang J wrote the first draft; Tong XM reviewed and edited the manuscript.
Supported by Key Research and Development Project of Science and Technology Department of Zhejiang Province, No. 2019C03038.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiang-Min Tong, MD, PhD, Chief Physician, Department of Hematology, Clinical Trial Institute, Zhejiang Provincial People’s Hospital, No. 158 Shangtang Road, Hangzhou 310014, Zhejiang Province, China. tongxiangmin@163.com
Received: April 15, 2021
Peer-review started: April 15, 2021
First decision: July 6, 2021
Revised: July 8, 2021
Accepted: September 8, 2021
Article in press: September 8, 2021
Published online: February 6, 2022
Core Tip

Core tip: We report a case of programmed cell death (PD)-1-inhibitor-induced autoimmune diabetes mellitus (DM) after treatment of small cell lung cancer, and reviewed some published cases (n = 36) of PD-1/PD-ligand 1 inhibitor-induced DM. Plasma glucose monitoring is significant for preventing the occurrence of diabetic ketoacidosis.